Markets:

Overview

News

Currencies

International

Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

108.81 -2.44 (-2.19%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Guardant Health Response to Frivolous and Retaliatory Lawsuit Filed by Illumina

March 17, 2022

From Guardant Health, Inc.

Via Business Wire

Guardant Health Receives Regulatory Approval for Guardant360® CDx in Japan

March 14, 2022

From Guardant Health, Inc.

Via Business Wire

Guardant Health's Return On Capital Employed Overview ↗

March 11, 2022

According to data from Benzinga Pro, during Q4, Guardant Health's (NASDAQ:GH) reported sales totaled $108.11 million. Despite a 32.75% increase in earnings, the company posted a...

Via Benzinga

10 Biggest Price Target Changes For Thursday ↗

February 24, 2022

SVB Leerink lowered Guardant Health, Inc. (NASDAQ: GH) price target from $170 to $140. Guardant Health shares dropped 5.7% to $56.22 in pre-market trading.

Via Benzinga

Recap: Guardant Health Q4 Earnings ↗

February 23, 2022

Guardant Health (NASDAQ:GH) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:03 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook

February 23, 2022

From Guardant Health, Inc.

Via Business Wire

The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development ↗

February 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...

Via Benzinga

Guardant Health to Participate in Upcoming Investor Conferences

February 07, 2022

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

February 01, 2022

From Guardant Health, Inc.

Via Business Wire

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium

January 19, 2022

From Guardant Health, Inc.

Via Business Wire

Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults

January 18, 2022

From Guardant Health, Inc.

Via Business Wire

Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation

January 07, 2022

From Guardant Health, Inc.

Via Business Wire

Why Jim Cramer Likes Vertiv And Scotts Miracle-Gro ↗

January 07, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Vertiv Holdings Co (NYSE:

Via Benzinga

Guardant Health to Participate Virtually in the 40th Annual J.P. Morgan Healthcare Conference

December 29, 2021

From Guardant Health, Inc.

Via Business Wire

Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR™-2 Blood Test to Detect Colorectal Cancer

December 17, 2021

From Guardant Health, Inc.

Via Business Wire

Guardant Health Presents Data Demonstrating Utility of Comprehensive Genetic Profiling with Guardant360® Liquid Biopsy Test to Guide Treatment for Advanced Breast Cancer Patients at 2021 San Antonio Breast Cancer Symposium

December 06, 2021

From Guardant Health, Inc.

Via Business Wire

4 Stocks Insiders Are Buying ↗

November 24, 2021

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t...

Via Benzinga

68 Biggest Movers From Wednesday ↗

November 26, 2021

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced its IPO at $10 per share. Longeveron Inc. (...

Via Benzinga

Topics Initial Public Offering

Detecting Early Cancer Screening Stocks At An Early Stage Is Critical ↗

November 22, 2021

If you're going to get cancer, you’re going to want to detect it early. While we’ve come a long way, baby, when it comes to treating terrible maladies like lung...

Via Benzinga

The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares ↗

November 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded...

Via Benzinga

Study Shows Guardant360® Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer

November 11, 2021

From Guardant Health, Inc.

Via Business Wire

Earlier Screening and Aging Population Driving Surging Growth in Colorectal Diagnostics Demand

November 11, 2021

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – November 11, 2021 – New recommendations for colorectal cancer (CRC) screening by both the US Preventative Services Task Force...

Via FinancialNewsMedia

Guardant Health to Participate in the 2021 Stifel Healthcare Conference

November 08, 2021

From Guardant Health, Inc.

Via Business Wire

Guardant Health Registers 27% Revenue Growth In Q3, Tops Consensus; Backs FY21 Guidance ↗

November 05, 2021

Guardant Health Inc (NASDAQ: GH) reported Q3 sales of $94.8 million, +27% Y/Y, beating the Wall Street estimate of $92.64 million. Guardant's Q3 precision oncology...

Via Benzinga

Guardant Health Inc (GH) Q3 2021 Earnings Call Transcript ↗

November 05, 2021

GH earnings call for the period ending October 30, 2021.

Via The Motley Fool

Topics Earnings

Guardant Health: Q3 Earnings Insights ↗

November 04, 2021

Guardant Health (NASDAQ:GH) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:03 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Guardant Health Reports Third Quarter 2021 Financial Results

November 04, 2021

From Guardant Health, Inc.

Via Business Wire

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

Guardant Health and The Royal Marsden NHS Foundation Trust Announce Partnership to Establish First Guardant Health Liquid Biopsy Testing Service Based in the United Kingdom

November 03, 2021

From Guardant Health, Inc.

Via Business Wire

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Guardant Health, Inc. - Common Stock (NQ:GH)

All News about Guardant Health, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today